Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report) gapped down before the market opened on Wednesday. The stock had previously closed at $38.10, but opened at $35.47. Carl Zeiss Meditec shares last traded at $35.48, with a volume of 4,922 shares traded.
Wall Street Analysts Forecast Growth
CZMWY has been the subject of several research analyst reports. The Goldman Sachs Group downgraded shares of Carl Zeiss Meditec from a “hold” rating to a “sell” rating in a research report on Monday, October 5th. Zacks Research raised Carl Zeiss Meditec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Morgan Stanley initiated coverage on Carl Zeiss Meditec in a research report on Wednesday, September 2nd. They set an “underweight” rating for the company. Finally, UBS Group lowered Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Strong Sell”.
Get Our Latest Analysis on CZMWY
Carl Zeiss Meditec Stock Down 5.1%
The stock has a 50 day moving average price of $36.77 and a 200 day moving average price of $32.99.
Carl Zeiss Meditec Company Profile
Carl Zeiss Meditec AG is a medical technology company headquartered in Jena, Germany, and part of the ZEISS Group. The company develops, manufactures and distributes equipment and solutions for ophthalmology and microsurgery, serving hospitals, clinics and medical professionals worldwide. Its ophthalmic portfolio includes diagnostic systems for examining the eye, equipment for cataract and refractive surgery, surgical lasers, intraocular lenses and other related products. The company also supplies surgical microscopes, visualization systems and digital technologies used in neurosurgery, spine surgery, ear, nose and throat procedures, and other microsurgical specialties.
Further Reading
- Five stocks we like better than Carl Zeiss Meditec
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.
